Slides
Page 1
NASDAQ: QIPT TSX: QIPTA Premier Provider of Clinical Respiratory Care Corporate Presentation May 2025
Page 2
Thispresent at ion(the“Present ati on”)aboutQuiptHomeMedicalCor p. (the“Company ”)is datedas of May 13, 2025. It is infor mati onin a summa ryformanddoesnotpurpor tto be com plete. It is notintendedto be relieduponas advi ceto invest orsor potentialinvest orsanddoesnotta keintoaccounttheinv estmentobjectiv es,financialsit uat ionor needsof any part icula rinvest or. No represent ati onor war ranty ,expr essor im pl ied,is madeor gi venby or on beha lfof theCom panyor any of its affi liat es,dir ect ors,officersor employ eesas to theaccur acy,complet enessor fairnessof theinfor mat ionor opinionscont ainedin thisPrese nt at ionand no responsi bi lit yor liabil ityis accept edby any personfor suchinfor mat ionor opinions. TheCompany doesnotunder tak eor agr eeto updat ethisPresent at ionor to cor rectanyinaccur aciesin, or omissi onsfrom,thisPresent at ionthatmaybecom eapparent. No personhasbeenauthorizedto gi veanyinfor mati onor ma keanyrepresent ati onsotherthanthosecont ainedin thisPresent at ionand,if gi venand/ormade,suchinfor mat ionor repr esent at ionsmustnotbe relied uponas havi ngbeenso authorized. Thecont entsof thisPresent at ionarenotto be const ruedas lega l,financialor taxadvi ce. Theinfor mat ioncont ainedhereinis consi deredcurrentas of thedateof thisPrese nt at ionbutwillnotbe updatedat any ti met her eafter. ThisPrese nt at iondoesnotcont ainall of theinfor mat ionthatwoul dnormall yappearin a prospectusor offeringmem or andumunderapplicableCanadiansecuri tieslaws. ThisPresent at ioncont ainsinfor mati onobtainedby theCom panyfromthirdpart ies,includi ngbutnotli mitedto mar ketdata. TheCom panybeliev essuchinfor mati onto be accur atebuthasnotindependent lyver ifi edsuchinfor mati on. To theext entsuchinfor mati onobtainedfromthirdpart ysources, thereis a risk thatthe assumpt ionsmadeand conclusi onsdraw nby the Companybasedon suchre pr esent ati onsare not accurat e. By youraccept anceof thispres entat ionyou and any personrev iewingthisPres entat ionag reesnot to dist ribut e,copy; repr oduce; t ransm it; ma keav ailable; or condoneany of the foregoing ,wit houtthe priorwr itt enconsentof the Com pany. Anyunauthorizeduseof thisPresent at ionis str ictl yprohibited. On yourri ghts,youareencoura gedto rev iewthisdisclosureandareadvi sedto consultindependentlega lcounsel,ta x,accounti ngand otheradvi sors. ThisPresent at ionis not,andundernocir cum stancesis tobeconst ruedas,a prospect us,offeringmem orandum,oran adver ti sementora publ icofferingof secur it ies,anddoesnotconsti tut eanofferforthesaleof securi ties. CAUT IONA RYNOT EREGARDINGFORW ARD-LOOKI NGINFORMAT IONANDFORW ARD-LOOKI NGST AT EMENTS: ThisPrese nt at ioncont ains“for ward-looki nginforma tion”wit hinthemea ni ngof Canadiansecur iti eslegi slat ionand“for ward-looki ngst ate ment s”wit hinthemea ni ngof applicablesecur iti esleg islat ion,includingtheUnitedSt at esPriv ateSecuri tiesLit igat ionReform Actof 1995(col lecti vel yreferr edto hereinas “for ward-look inginform ati on”or “for war d-look ingst at ement s”). Any st at ement sthat expr ess,or inv ol vediscussionsas to, expecta ti ons ,beliefs,plans, objecti ves ,assum pt ionsor fut ureevent sor perform anceare nothist ori calfact sand may be forwar d-look ingand may inv ol veest ima tes,assum pt ionsand unce rta int ies whichcouldcauseactualresult sor outcomesto differmat erial lyfromthoseexpr essedin the forwar d-looki ngst ate ment s. For ward-looki ngst ate ment sare includedto provi deinforma tionaboutma nagem ent’ scurrentexpect ati onsand plansin an effortto allowinv estorsand othersto get a bett erundersta ndi ngof the Company’soperati ngenvi ronment,business oper ati onsandfinancialperform anceand condit ion.Forw ard-looki nginfor mati onisprovidedasofthedateofthisPresent at ionandtheCom panydoesnotintend,anddoesnotassumeanyobligat ion,toupdat ethisfor ward-looki nginformat ion,exceptasrequiredbylaw. Any st atem entsthatexpr essor involv ediscussionswit hrespectto predicti ons,expect at ions,beliefs,plans,proj ect ions,objectiv es,assumpt ionsor fut ureeventsor performanceoft en,but not alw ays,identifiedby wordsor phrasessuchas “pl ans”,“expects”or “doesnot expect”,“i sexpected”,“budget ”,“pot ent ial”,“scheduled”,“esti mat es”,“forecast s”,“intends”, “anti cipat es”or “doesnotanti cipat e”,or “bel iev es”,or va riat ionsof suchwordsand phrasesor st atem entsthatcertai nacti ons,eventsor result s“will”,“may ”,“could”,“would”,“mig ht”or “willbe t aken”,“occur”or “be achiev ed”(or the negat iveof theset ermsor comparabl et ermi nol og y)are notst ate mentsof factand maybe forwar d-looki ngst ate ments. For ward- looki ngst ate ment sinclude,butare notli mit edto, st ate ment sreg ardingthe anti ci pat edrev enueand EBITDAma rgi nfor the Companyoverthe nextfi veyea rs,infor mat ionwit hrespectto fut uregr owthandgr owthst rat egi es,anti ci pat edtr endsin ourindustry ,ouracqui siti onst rat egy ,andexpect ati onsas to theeffectof theCOVID-19pandemicon theCompany’sbusiness andoperat ions. Forw ard-looki nginfor mati onand for wardlookingst atem entsare basedon the reasonableassum pti ons,esti mat es,analysi sand opinionsof the Com pany’sma nagem entmadein lig htof its exper ienceand its perceptionof tr ends,cur rentcondit ionsand expecteddevel opm ent s,as wellas other fact or sthatma nagem entbeliev esto be relev antand reasonablein the cir cum stancesat thedatethatsuchst ate mentsarema de,butwhichmayproveto be incorrect. TheCompanybeliev esthattheassumpt ionsandexpect ati onsreflectedin suchforwar d-looki nginfor mat ionarerea sonabl e. If suchfact orsorassumpt ionsproveuntrue,actualresult s,performa nceorachiev ementsmaybemat erial lydiffer entfromfut ureresult s,performa nceor achievem entsexpr essedorim pl iedbysuchst atem ents. By theirver ynature,for ward-looki ngst atem entsrequirethe Com panyto mak eassumpt ionsand are subjectto knownand unknownri sk s,uncer tai nt iesand otherfact or swhichmay causethe actualresult s,performanceor achievem entsof the Companyto be mat erial lydifferentfromany fut ureresult s,performa nceor achiev ementsexpr essedor im pl iedby the for ward-looki ngst atem ents. A va rietyof mat eri alfact or sinclude,amongothers: creditri sk s,mar ketri sk s(includingthoserela tedto equi ty,for eignexchangeand inter estrat ema rket s),liquidityri sk s,operat ionalri sk s(includingthoserela tedto technologyand infra str uct ure),and ri sk srela tingto reputat ion,insurance,st rat egy ,regula toryma tt ers,lega lma tt ers, envi ronmenta lma tt ers,capi taladequacyand ri sk srela tedto the COV ID-19pandemic. Examplesof suchriskfact orsinclude: the Companymaybe subjectto signi ficantcapi talrequir ementsandoper ati ngri sk s; changesin law,theabilit yto im plementbusinessst rat egi es,gr owthst rat egi esandpursuebusinessoppor tunit ies; st ateof thecapitalma rke ts; theav ailabil ityof fundsand resourcesto pursueoperat ions; decl ineof rei mbursementrat es; dependenceon few payors; possi bl enewdrugdiscoveri es; a novelbusinessmodel; dependenceon key suppli ers; gr ant ingof permit sand li censesin a highlyregula tedbusiness; com petit ion; difficult yint egrat ingnewlyacquir edbusinesses; low profi tmar ketsegm ent s; disruptionsin or at ta ck s (includingcyber-at ta ck s)on infor mati ontechnology,int ernet,networ kaccessor othervoiceor datacommuni ca ti onssyst emsor serv ices; theevolut ionof va riousty pesof fraudor othercrimi na lbehavi our; the failureof thirdpart iesto com plywit htheirobligat ions; theim pactof new and changesto,or applicati onof, currentlawsand reg ulat ions; theovera lldiffi cult li ti gat ionenvi ronment ,includingin theUnitedSt at es; increas edcompet it ion; changesin for eigncurrencyrat es; lossof for eignpriv ateissuer st at us; ri sksrel atingto thedeter iora tionof gl obaleconom iccondit ions; increas edfundingcostsand ma rketvol atil itydueto ma rketill iqui di tyand compet it ionfor funding; crit icalaccount ingest imat esand changesto account ing st anda rds,policies,and met hods; theoccurr enceof naturaland unnatura lcat astr ophicevent sand claim sresult ingfromsuch ev ent s; and ri sk srela tedto COV ID-19includi ngva riousrecomm endat ions,ordersand mea sur esof gov ernment alaut hor iti esto tr yto lim itthepandemic,includingtr avelres tr icti ons,borderclosures,non-essenti albusinessclosures,quarant ines, self-isolat ions,shelt er s-in-pla ceandsoci aldist anci ng,disrupti onsto ma rke ts,econom icacti vi ty,financing,supplychai nsand saleschannel s,and a deter iorat ionof gener aleconom iccondit ionsincludinga possi blenati onalor gl obalrecession; as wellas thoseriskfact orsdiscussedor referredto in the Company’sdisclosuredocum ent sfiledwit hthesecur iti esreg ul atory authorit iesin certai nprovi ncesofCanadaandav ailableatwww.sedar.com. Thislistis notexha ust iv eof thefact orsthatmayaffectany of theCompany’sforwar d-looki ngst at ement s. Al thoughtheCompanyhasat te mpte dto identi fyim por ta ntfactorsthatcoul dcause actualacti ons ,event sor result sto differmat eria llyfromthosedescribedin forwar d-looki ngst at ement s,ther emaybe otherfact orsthatcauseacti ons,event sor result snotto be as anti cipat ed,esti mat edor intended. TheCom panyprovidesno assurancethatfor ward-looki ngst atem entswillproveto be accur ate,as actualresult sandfut ureeventscoulddiffermat erial lyfromthose anti cipat edin suchst atem ents. NON-GAA PMEA SURES: ThisPresent at ionrefersto “AdjustedEB ITDA”and “AdjustedEBITDAMarg in”whichare non-GAAPand non-IFRSfinancialmeasur esthatdo nothavestandardizedmeani ng sprescribedby GAAPor IFRS. The Com pany’spresent at ionof thesefinancialmeasur esmaynotbe com parableto simi larl yti tledmeasur esusedby othercom panies. These financialmeasur esare intendedto provideadditi onalinfor mati onto invest orsconcerningthe Com pany’sperformance. Adjust edEBITDAis defi nedas EBITDAexcludingst ock-basedcom pensa tion. Adjust edEBITDAis a Non- IFRSmeasur etheCom panyusesas an indicatorof financialhealthand excludessever alit emswhichmaybe usefulin the consi der ati onof the financialcondit ionof theCom pany,includi nginter estexpense,incometa xes,depreciat ion,am orti zat ion,stock-basedcom pensa tion,goodwill This presentation refers to “Annualized Revenue”, “R ecurring Revenue”, “Adjusted EBITDA”, “Annualized Adjusted EBITDA” and “Anticipated Annualized Adjusted EBITDA”, which are non-GAAP and non-IFRS financial measures that do not have standardized meanings prescribed by GAAP or IFRS. The Company’s presentation of these financial measures may not be comparable to similarly titled measures used by ot her companies. These financial measures are int ended to provide addit ional information to inv estors concerning the Company’s performance. Forward Looking Statements
Page 3
Quipt Overview
Page 4
4 Financial and Operational Highlights ▪ Quipt Home Medical Corp. is a premier provider of clinical respiratory care in the home setting throughout the U.S.A ▪ 5th largest HME provider in the country headquartered in Wilder, Kentucky with 130 locations and over 1,200 employees ▪ Multiple organic and external growth opportunities backed by strong industry fundamentals ▪ $35.4 Million in Cash Flow from Operations for the twelve months ended September 30, 2024 ▪ Dual listed in the US and Canada: NASDAQ (QIPT) | TSX (QIPT) 1) Revenue and Adjusted EBITDA based off the Company’s twelve months ended September 30, 2024 314,000 Patient Lives 36,000 Referring Physicians 26 Active States $245.9M FY2024 Revenue(1) $57.9M FY2024 Adj. EBITDA(1) 850,000+ Annual Deliveries Strong Foundation for Continued Growth
Page 5
5 Q2 2025 Investment Highlights 81% Recurring Revenue (2) 1.5x Net Debt to EBITDA Leverage (2) $18.2 Million Cash Flow from Operations(1) $47.8 Million Liquidity to fund future growth (2) ~10% Insider Ownership Consistent Demand for Diversified Product Mix ❖ Significant market growth opportunity due to rising need for home-based care ❖ ~10k Americans turn 65 every day, leading to increased healthcare utilization Robust and Resilient Business Model ❖ End-to-end solution provides a unique go to market strategy ❖ Operating leverage drives consistent margin performance ❖ 8-10% organic growth target Management Expertise in Value Creation ❖ Proven history of margin strength and stability ❖ Successful integration of over 19 acquisitions generating >$150 million in revenue ❖ Substantial insider ownership 1) Figures as of the six months ended March 31, 2025. 2) Figures as of the three months ended March 31, 2025.
Page 6
6 Our History and Path Forward Our History of Growth Our Path Forward ▪ Utilize robust balance sheet and flexible capital allocation strategy to create value for shareholders through sustained organic growth and opportunistic NCIB purchases ▪ Capitalize on opportunities for cross-selling, expansion of health network, and growth in continuum markets ▪ Continued implementation of a highly selective acquisition strategy focused on synergistic acquisitions that are healthcare system focused and garner additional scale in attractive geographies ▪ Focus on expanding into regions with high prevalence of COPD patients 15 States Covered August 2021 Surpassed $100 Million Revenue Fiscal 2021 Dual Listed on NASDAQ May 2021 Surpassed $245 Million Revenue Fiscal 2024 39.3% 4-Year A. EBITDA CAGR 26 States Covered December 2023
Page 7
7 Strong Recurring Revenue Base & Diverse Payor Mix Revenue Mix (1) Payor Mix (1)Service Mix (1) 1)Updated annually
Page 8
8 Substantial Operations and Targeted Expansion ✓ 130 locations across 26 states ✓ Solidified Midwest & Southeast presence ✓ Strengthening coast to coast reach Current Operations ✓ Continued focus on expanding into regions with high prevalence of COPD patients ✓ Significant opportunity to penetrate existing underpenetrated markets ✓ Targeting nationwide scale Targeted Expansion
Page 9
9 Industry Tailwinds Support Organic Growth 10,000 Americans turning 65 everyday (1) 16 Million COPD patients in the US alone (2) 80 Million Estimated US population impacted by Sleep Apnea(3) 31.7% Of all Americans suffer from at least 2 or more chronic conditions (4) 141 149 157 164 171 40 46 56 65 73 0 50 100 150 200 2010A 2015A 2020A 2025P 2030P Chronic Conditions 65+ Population U.S. Aging (1) & Chronic Condition Population (5) 1) US Census Bureau 2) US Dept of Health 3) Clarivate DRG. (2021) 4) Agency for Health Research and Quality 5) American Hospital Agency Millions
Page 10
Resupply census continues to be strong, with no increase in attrition rates Quipt has experienced no slowdown in CPAP set- ups and continues to see strong referral patterns Data analysis of 1,359,000 patients shows positive correlation between GLP-1s and PAP therapy(1) Patients with OSA diagnosis and prescribed a GLP-1 drug are 10.8% more likely to initiate PAP therapy(1) Majority of 80 million estimated to be impacted with sleep apnea are undiagnosed Patients with an OSA diagnosis and prescribed a GLP-1 drug have higher PAP resupply rates 1- year and 2-years post-setup(1) Complimenting Usage of GLP-1s Positive Correlation Between GLP-1s and PAP Therapy Strong Demand and Significant Patient Population 1) Resmed Earnings Presentation –April 23, 2025
Page 11
Market Positioning
Page 12
12 Sales Team Sales Touchpoints Verification & Distribution Delivery & Education Revenue Cycle Order Life Cycle ✓ The Order Life Cycle begins with Quipt’s field sales team and ends with successful collections by Quipt’s revenue cycle team ✓ Key sales touch points include hospitals, doctor's offices, rehab centres and long-term care facilities ✓ Quipt’s ordering platform integrates all facets of the ordering process to ensure exceptional patient satisfaction End-to-End Product Solution Drives Unique Market Positioning
Page 13
Diversified Product Mix Drives Go-to-Market Strategy Sleep Therapy Home Oxygen Therapy Ventilation Therapy Percussion Vests Custom Mobility HME & Other Services 13
Page 14
✓ Live monitoring allows for monitoring treatment plan effectiveness ✓ Identify and drive early intervention, if needed ✓ Reduces hospitalizations and improves outcomes ✓ Remote patient monitoring capabilities Connected Healthcare VentilatorSleep Apnea OxygenNebulizer Patient Centric Ecosystem 14 Select Respiratory Devices
Page 15
✓ In-home (or on-site) delivery across 26 states, and expanding ✓ Quipt has a robust team of certified respiratory therapists ✓ Proper use of prescribed equipment is explained in a 1-on-1 environment to ensure long-term patient compliance, comfort, and care Responsible Equipment Delivery In-Home Delivery & Set Up 15
Page 16
Growth Strategy
Page 17
Debt Management ❖ $47.8 million of current liquidity (cash on hand and revolver availability) ❖ Current leverage at 1.5x net debt to EBITDA ❖ Maintain leverage at <2.5x net debt to EBITDA Organic Growth ❖ 8-10% annualized growth target ❖ Focus on sales force penetration and continued expansion into continuum markets ❖ Enhancement of service offerings and increase cross-selling of products ❖ Use of technology to Improve operational efficiencies Synergistic Acquisitions ❖ Focus on healthcare system owned DME providers ❖ Expand geographic footprint into attractive markets ❖ Preferred provider agreements for hospital discharge-driven care ❖ Enhance insurance portfolio ❖ Respiratory focused product mix ❖ Patient base expansion Strategic Growth Initiatives 17 Operating Leverage ❖ Focus on economies of scale and operational efficiencies to increase margins ❖ Focus on effective billing and compliance ❖ Continued technology refinements ❖ Continued growth of re-supply program
Page 18
18 Driving Economies of Scale Consistent and Strong Margin Profile ✓ Scale promotes operating leverage driving margin consistency and strong compounding growth ✓ Since 2018, Quipt has utilized organic growth and synergistic acquisitions to drive scale ✓ Technology utilization eliminates friction points driving margin improvement Revenue (millions) Adj. EBITDA Margin (%) * The Company transitioned from IFRS to U.S. GAAP reporting standards effective Fiscal Q4 and Full Year 2024, following its designation as a U.S. Domestic Filer. The corresponding period in 2023 also reflects the transition. Prior to 2023 is under IFRS standards.
Page 19
19 Technology Utilization Organizational Efficiency Revenue Cycle Finance & Accounting Order Fulfillment Project Management ✓ Automated, real-time reporting informs data driven decision making ✓ Uniform reporting structures create opportunities for increased collaboration ✓ Commitment to technology will always remain a core focus of the Company
Page 20
Financial Profile
Page 21
21 Financials: Q2 2025 ▪ 23.3% Adjusted EBITDA Margin ▪ 81% Recurring Revenue ▪ Net Debt to Adjusted EBITDA of 1.5x Financial Highlights ▪ Successfully expanded the Company’s product portfolio ▪ Referral network expansion efforts accelerated, deepening engagement with physicians, hospitals, and health systems ▪ Introduced the Quipt Sales Accelerator program, a new initiative to enhance sales team performance Operational Highlights Revenue (millions) Adj. EBITDA (millions) Q2 2025 Revenue & Adj. EBITDA Transitioned from IFRS to GAAP * The Company transitioned from IFRS to U.S. GAAP reporting standards effective Fiscal Q4 and Full Year 2024, following its designation as a U.S. Domestic Filer. The corresponding period in 2024 also reflects the transition. Prior to 2024 is under IFRS standards.
Page 22
22 Financials: Full Year 2024 ▪ 16.2% increase in Total Revenue ▪ 14.3% increase in Adjusted EBITDA ▪ 23.5% Adjusted EBITDA margin ▪ $35.4mm positive cashflow from operations Financial Highlights ▪ 10% increase in unique patient base ▪ 13% increase in total resupply set-ups and/or deliveries ▪ 21% increase in patients in resupply program Operational Highlights Revenue (millions) Adj. EBITDA (millions) Annual Revenue & Adj. EBITDA Transitioned from IFRS to GAAP * The Company transitioned from IFRS to U.S. GAAP reporting standards effective Fiscal Q4 and Full Year 2024, following its designation as a U.S. Domestic Filer. The corresponding period in 2023 also reflects the transition. Prior to 2023 is under IFRS standards.
Page 23
$76 Million Market Cap* $161 Million Enterprise Value* 43.1 Million Basic Shares Outstanding $30.7 Million Senior Credit Facilities (Available) $17.1 Million Cash and Cash Equivalents Capital Structure & Insider Ownership ~10% Insider Ownership 23 * As of May 13, 2025
Page 24
24 Management Team Greg Crawford,CEO & Chairman - Greg Crawford is an accomplished executive with more than 30 years of healthcare services experience, focused on the durable medical equipment industry. With a proven track record of success in both the private and public sector, Greg adds extensive operational, integration, and M&A experience to his role as Quipt's Chief Executive Officer and Chairman. Since joining in that role in 2017, Greg spearheaded a comprehensive restructuring plan that revitalized the company's operations and strategic direction. Greg has successfully led the Company in its robust growth from $50 million in annualized revenue to a multi-hundred-million-dollar revenue business and accelerated margins through innovative growth strategies, operational efficiency improvements, and accretive acquisitions. The ability to balance Quipt’s core mission of clinical excellence and margin enhancement in today’s challenging ecosystem is a testament to his strong leadership. Greg’s visionary approach, combined with his unyielding commitment to the company’s market positioning, has seen Quipt emerge into a growing force in the durable medical equipment industry. Greg joined Quipt through Quipt’s purchase of Patient-Aids, Inc. Greg began working at Patient-Aids in 1994, becoming a partner 3 years later and Patient-Aids' sole owner in 2004. During the period of his ownership, Patient-Aids grew from less than $1 million to $20 million of revenue and quadrupled its earnings through organic growth and strategic acquisitions. Greg’s exceptional ability to build teams and lead under challenging circumstances coupled with his strategic acumen and focus on sustainable growth continues to steer Quipt towards greater success. Thomas Roehrig, EVP Finance - Tomis a CPAand has over 30 yearsof hands-on experiencein accountingand finance. His background includesbeing the Chief AccountingOfficer of a publicly-traded US company. He brings significant experience in public company financial reporting,debt and equity financings,inventory management,and acquisitiontransactions. His prolific career significantly broadens QHM’sinternal capabilitiesin these areas at this pivotal point in the Company’s development. Hardik Mehta, CFO - Hardik Mehta has worked as a finance professionaland an investmentbanker at investmentbanking and advisory firm, SilverstoneCapital Advisorsfor nearly ten years. Hardikhas significantacquisition,transaction,finance and accountingexperience. Hardikhas been an advisor on morethan 30 M&A and funding transactions,includingbuy-side transactionsand post-transaction integrationplanning.
Page 25
25 Board of Directors Brian J. Wessel, Independent Director - Mr. Wessel is a senior business executive with over 34 years of global client service, operational and financial expertise. As a former senior partner at Ernst & Young (“EY”), Mr. Wessel provided audit and advisory services to public, private, and private-equity-owned companies across multiple industry sectors. Additionally, Mr. Wessel led EY’s Capital Markets practice group in Mexico overseeing various foreign private issuers listed on the U.S., European and Japanese stock exchanges. Mr. Wessel has a compelling executive track record of successfully leading through complex business transactions and advising companies on accounting, auditing and financial reporting matters. Mr. Wessel adds significant knowledge and practical experience in complex accounting and financial reporting matters, SEC registration statements, business combinations, audits of internal control over financial reporting and carve-out audits. Furthermore, Mr. Wessel has deep experience with various types of transactions including business acquisitions and divestitures. Mark Greenberg, Independent Director - Mark Greenberg is the Managing Partner and Founder of Silverstone Capital Advisors, a boutique investment banking and advisory firm located in Cincinnati, Ohio. Mark brings 30 years of senior executive operating and transaction expertise and experience. He has led and participated in more than 150 M&A and capital funding transactions during his career. Mark’s clients include both privately-held and public companies throughout the U.S. In addition to Quipt, Inc.’s board, Mark serves on 4 company boards of directors. Dr. Kevin A. Carter,IndependentDirector - Kevin A. Carter, DO, FAASM, is Board Certified in Sleep Medicine by the American Board of Family Medicine; he is also Board Certified in Family Practice. Dr. Carter holds the degree of Fellow by the American Academy of Sleep Medicine and has Dr. Carter has formerly served as a Medical Director at the United States Army Sleep Medicine Center at Fort Benning, Georgia. Prior to this appointment, he served as a United States Army Field Surgeon, with service including deployment in Iraq. Dr. Carter is a graduate of the Ohio University of College of Osteopathic Medicine. He is also an active member of both the American Academy of Sleep Medicine and the American Academy of Family Physicians. Greg Crawford,CEO & Chairman - Greg Crawford is an accomplished executive with more than 30 years of healthcare services experience, focused on the durable medical equipment industry. With a proven track record of success in both the private and public sector, Greg adds extensive operational, integration, and M&A experience to his role as Quipt's Chief Executive Officer and Chairman. Since joining in that role in 2017, Greg spearheaded a comprehensive restructuring plan that revitalized the company's operations and strategic direction. Greg has successfully led the Company in its robust growth from $50 million in annualized revenue to a multi-hundred-million-dollar revenue business and accelerated margins through innovative growth strategies, operational efficiency improvements, and accretive acquisitions. The ability to balance Quipt’s core mission of clinical excellence and margin enhancement in today’s challenging ecosystem is a testament to his strong leadership. Greg’s visionary approach, combined with his unyielding commitment to the company’s market positioning, has seen Quipt emerge into a growing force in the durable medical equipment industry. Greg joined Quipt through Quipt’s purchase of Patient-Aids, Inc. Greg began working at Patient-Aids in 1994, becoming a partner 3 years later and Patient-Aids' sole owner in 2004. During the period of his ownership, Patient-Aids grew from less than $1 million to $20 million of revenue and quadrupled its earnings through organic growth and strategic acquisitions. Greg’s exceptional ability to build teams and lead under challenging circumstances coupled with his strategic acumen and focus on sustainable growth continues to steer Quipt towards greater success.
Page 26
Cole Stevens 859-300-6455 cole.stevens@myquipt.com www.quipthomemedical.com Contact Information